Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑spec···【more】
Release date：2026-03-20Recommended：200
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administ···【more】
Release date：2026-03-20Recommended：229
Cabozantinib is a small-molecule multi-targeted tyrosine kinase inhibitor develo···【more】
Release date：2026-03-20Recommended：177
Cabozantinib is a broad‑spectrum multi‑targeted anticancer drug that inhibits at···【more】
Release date：2026-03-20Recommended：170
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 inhibitor ···【more】
Release date：2026-03-19Recommended：260
Lorlatinib was first approved in Japan in September 2018, followed by approval f···【more】
Release date：2026-03-19Recommended：327
Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts ant···【more】
Release date：2026-03-19Recommended：237
Dabrafenib is a kinase inhibitor developed by Novartis Pharmaceuticals. It was f···【more】
Release date：2026-03-19Recommended：172
Sparsentan, developed by Travere Therapeutics, is a dual receptor antagonist tha···【more】
Release date：2026-03-18Recommended：231
Sparsentan, developed by Travere Therapeutics, is an endothelin and angiotensin ···【more】
Release date：2026-03-18Recommended：266
During treatment with Sparsentan, regular monitoring is required. Follow-up shou···【more】
Release date：2026-03-18Recommended：200
Sparsentan is the first dual pathway blocker. Its usage and dosage should be det···【more】
Release date：2026-03-18Recommended：226
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
